TherapeuticsMD Inc. (NASDAQ:TXMD)’s traded shares stood at 7.08 million during the last session, with the company’s beta value hitting 1.88. At the close of trading, the stock’s price was $0.71, to imply a decrease of -1.95% or -$0.01 in intraday trading. The TXMD share’s 52-week high remains $2.75, putting it -287.32% down since that peak but still an impressive 0.0% since price per share fell to its 52-week low of $0.71. The company has a valuation of $301.77M, with an average of 5.05 million shares in intraday trading volume over the past 10 days and average of 5.66 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for TherapeuticsMD Inc. (TXMD), translating to a mean rating of 1.70. Of 4 analyst(s) looking at the stock, 0 analyst(s) give TXMD a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.1.
TherapeuticsMD Inc. (NASDAQ:TXMD) trade information
After registering a -1.95% downside in the last session, TherapeuticsMD Inc. (TXMD) has traded red over the past five days. The stock hit a weekly high of 0.7884 this Thursday, 09/16/21, dropping -1.95% in its intraday price action. The 5-day price performance for the stock is -8.23%, and -7.53% over 30 days. With these gigs, the year-to-date price performance is -41.38%. Short interest in TherapeuticsMD Inc. (NASDAQ:TXMD) saw shorts transact 32.34 million shares and set a 5.72 days time to cover.
Analysts on Wall Street suggest a consensus price target of $4.75, implying an increase of 85.05% to the stock’s current value. The extremes give us $4.00 and $5.00 for target low and target high price respectively. As such, TXMD has been trading -604.23% off suggested target high and -463.38% from its likely low.
TherapeuticsMD Inc. (TXMD) estimates and forecasts
Looking at statistics comparing TherapeuticsMD Inc. share performance against respective industry, we note that the company has outperformed competitors. TherapeuticsMD Inc. (TXMD) shares are -52.71% down over the last 6 months, with its year-to-date growth rate higher than industry average at 43.06% against 18.10%. Revenue is forecast to grow 16.70% this quarter before jumping 40.00% for the next one. The rating firms project that company’s revenue will grow 50.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is $25.87 million. Meanwhile, for the quarter ending Dec 2021, a total of 4 analyst(s) estimate revenue growth to $29.19 million.Earnings reports from the last fiscal year show that sales brought in $19.34 million and $22.58 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 33.70% before jumping 29.30% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -6.30% for the past 5-year period. While 2021 is set for a 6.90% return in earnings, projections for the next 5 years are at 17.60% annually.
TherapeuticsMD Inc. has its next earnings report out on May 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. TherapeuticsMD Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
TherapeuticsMD Inc. (NASDAQ:TXMD)’s Major holders
TherapeuticsMD Inc. insiders hold 8.02% of total outstanding shares, with institutional holders owning 46.20% of the shares at 50.23% float percentage. In total, 46.20% institutions holds shares in the company, led by Blackrock Inc. As of Jun 29, 2021, the company held over 24.84 million shares (or 5.86% of shares), all amounting to roughly $29.56 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 18.61 million shares, or about 4.39% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $22.15 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the TherapeuticsMD Inc. (TXMD) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 9.54 million shares. This is just over 2.25% of the total shares, with a market valuation of $12.78 million. Data from the same date shows that the other fund manager holds a little less at 8.32 million, or 1.96% of the shares, all valued at about 9.9 million.